Abstract
Malaria is a mosquito-borne infectious disease caused by the parasite Plasmodium spp. Malaria continues to have a devastating impact on human health. Sporozoites are the infective forms of the parasite inside mosquito salivary glands. Circumsporozoite protein (CSP) is a major and immunodominant protective antigen on the surface of Plasmodium sporozoites. Here, we report a generation of specific monoclonal antibodies that recognize the central repeat and C-terminal regions of P. falciparum CSP. The monoclonal antibodies 3C1, 3C2, and 3D3—specific for the central repeat region—have higher titers and protective efficacies against challenge with sporozoites compared with 2A10, a gold standard monoclonal antibody that was generated in early 1980s.
Highlights
In 2015, there were 214 million new cases of malaria and an estimated438,000 malaria deaths worldwide [1]
We examined the protection of the P. falciparum CSP (PfCSP) monoclonal antibody (mAb) against malaria sporozoite challenge in vitro and in vivo
We found that mAb 3C1, 3C2, and 3D3 significantly inhibited the parasite development in Hepa 1–6 cells compared with 2A10, which is an effective mouse mAb specific for the
Summary
In 2015, there were 214 million new cases of malaria (range 149–303 million) and an estimated. 438,000 malaria deaths (range 236,000–635,000) worldwide [1]. Malaria is a mosquito-borne disease caused by the protozoan parasite, Plasmodium spp. Malaria is transmitted among humans by the bite of female mosquitoes of the genus Anopheles. The battle against malaria has been fought using a wide range of interventions, including insecticide-treated bed nets, indoor residual spraying, effective medicines, and vaccine [2,3,4,5]. Emerging antimalarial drug resistance and insecticide resistance threaten malaria control and public health [6,7,8]. The only approved malaria vaccine is RTS,S/A01 (trade name Mosquirix) to date. RTS,S/A01 represents it’s composed of P. falciparum
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
